You are viewing: US Neuromodulation Market analysis
Part of: Neuromodulation Market (Global)

The US Neuromodulation Market was valued at $2893.1 Million in 2025 and projected to reach to $4470.6 Million by 2030, representing a compound annual growth rate of 9.1%. The US neuromodulation market is poised for sustained growth through 2030, driven by an aging population, rising prevalence of chronic pain conditions, and expanding FDA approvals for novel neuromodulation therapies.

US Neuromodulation Market Trends and Insights

  • The US market benefits from advanced healthcare infrastructure, high adoption rates of innovative medical technologies, and strong reimbursement frameworks that support neuromodulation device deployment across pain management, movement disorders, and neurological conditions.
  • The US represents a mature yet rapidly evolving market where both established players and emerging innovators compete to capture growing demand from an aging population and increasing prevalence of chronic neurological conditions. Driving growth in the US neuromodulation market are rising incidences of Parkinson's disease, epilepsy, and chronic pain syndromes, coupled with expanding clinical evidence supporting device efficacy.
  • The US healthcare system's emphasis on minimally invasive treatments and patient outcomes has accelerated adoption of spinal cord stimulation, deep brain stimulation, and peripheral nerve stimulation technologies.
  • Regulatory pathways in the US, including FDA clearances and breakthrough device designations, continue to facilitate rapid market entry for next-generation neuromodulation solutions, positioning the US as a global innovation hub for the sector..

Key Market Statistics

  • CAGR (2025-2030) 9.1% CAGR
  • Market Size, 2025 ~USD 2893.1 Million
  • Forecast, 2030 ~USD 4470.6 Million
  • Country US

US Neuromodulation Market Overview

Market Size & Growth :

The US neuromodulation market is valued at $2,893.1 million in 2025 and is projected to reach $4,470.6 million by 2030, representing a robust 9.1% CAGR driven by increasing chronic pain prevalence and neurological disorder diagnoses.

Advanced Healthcare Infrastructure :

The US benefits from state-of-the-art medical facilities, cutting-edge research institutions, and early adoption of innovative neuromodulation technologies, positioning it as a leader in device innovation and clinical applications.

Strong Reimbursement Framework :

Favorable Medicare and private insurance coverage policies support widespread deployment of neuromodulation devices for pain management, Parkinson's disease, epilepsy, and other neurological conditions, reducing patient out-of-pocket costs.

High Technology Adoption Rates :

US healthcare providers and patients demonstrate strong preference for minimally invasive neuromodulation solutions, including spinal cord stimulation, deep brain stimulation, and peripheral nerve stimulation devices.

US Neuromodulation Market Dynamics

  • Technological advancements in device miniaturization, wireless capabilities, and AI-integrated systems are enhancing treatment efficacy and patient outcomes.
  • Additionally, increasing healthcare expenditure and growing awareness among physicians and patients about neuromodulation benefits are accelerating market penetration across diverse therapeutic areas including pain management, movement disorders, and psychiatric conditions. Key growth catalysts include the expansion of reimbursement coverage, clinical evidence supporting long-term efficacy, and strategic investments by major medical device manufacturers in US-based R&D facilities.
  • The market will likely see increased competition, pricing pressures, and consolidation among smaller players.
  • Emerging opportunities exist in remote monitoring capabilities, personalized treatment algorithms, and combination therapies that integrate neuromodulation with pharmacological interventions..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • The US neuromodulation market will grow from $2,893.1M (2025) to $4,470.6M (2030) at a 9.1% CAGR.
      • The US market is driven by aging demographics, rising chronic neurological disease prevalence, and strong reimbursement coverage.
      • FDA regulatory pathways and breakthrough device designations accelerate innovation adoption in the US market.
      • The US remains the largest and most mature neuromodulation market globally, attracting significant R&D investment.

      Neuromodulation Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment DEEP BRAIN STIMULATION (Stimulation Type)
      Forecast Period 2025–2030
      Growth Rate CAGR of 9.4% from 2025 to 2030
      Largest Segment INTERNAL NEUROMODULATION (Technology)
      Market Size Base Year (Billions) ~USD 6.82 (2025)
      Revenue Forecast (Billions) ~USD 10.68 (2030)
      Segments Covered Technology, Stimulation Type, Application, End User

      US Neuromodulation Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Technology

      • External Neuromodulation
      • Internal Neuromodulation

      By Stimulation Type

      • Deep Brain Stimulation
      • Gastric Electrical Stimulation
      • Other Stimulation Types
      • Respiratory Electrical Stimulation
      • Sacral Nerve Stimulation
      • Spinal Cord Stimulation
      • Transcranial Magnetic Stimulation
      • Transcutaneous Electrical Nerve Stimulation
      • Vagus Nerve Stimulation

      By Application

      • Chronic Pain
      • Depression
      • Epilepsy
      • Failed Back Surgery Syndrome
      • Fecal Incontinence
      • Gastroparesis
      • Ischemia
      • Migraine
      • Obesity
      • Other Deep Brain Stimulation Applications
      • Other Transcutaneous Electrical Nerve Stimulation Applications
      • Other Vagus Nerve Stimulation Applications
      • Parkinson’S Disease
      • Treatment-Resistant Depression
      • Tremor
      • Urine Incontinence

      By End User

      • Clinics & Physiotherapy Centers
      • Hospitals & Ambulatory Surgery Centers
      • Other End Users

      Target Audience

      • Medical Device Manufacturers : Neuromodulation device companies need US-specific market data to benchmark performance, identify growth segments, optimize pricing strategies, and plan product portfolio expansion in the world's largest neuromodulation market.
      • Healthcare Investors & PE Firms : Investment professionals require detailed US market analysis, growth projections, and competitive dynamics to evaluate acquisition targets, assess portfolio company performance, and identify high-potential investment opportunities.
      • Hospital & Healthcare Systems : Healthcare administrators and procurement teams need market insights to make informed decisions about neuromodulation device adoption, vendor selection, budget allocation, and clinical program development.
      • Pharmaceutical & Biotech Companies : Companies exploring combination therapies or adjacent markets need US neuromodulation market intelligence to identify partnership opportunities, assess competitive threats, and evaluate market entry feasibility.
      • Market Research & Consulting Firms : Research organizations require comprehensive US market data to support client advisory services, validate market models, develop competitive intelligence reports, and provide evidence-based strategic recommendations.

      Key Companies in the US Neuromodulation Market

      CompanyHQOwnershipStrongest segments
      BIOGENUnited StatesPublic CompanyInternal neuromodulation (implanted SCS/DBS/VNS-aligned adjacencies),External neuromodulation (non-invasive stimulation adjacencies),Spinal cord stimulation–linked care pathways,
      MEDTRONICIrelandPublic CompanyInternal neuromodulation – Spinal Cord Stimulation,Internal neuromodulation – Deep Brain Stimulation,Internal neuromodulation – Vagus Nerve and Other Implants,
      BOSTON SCIENTIFIC CORPORATIONUnited StatesPublic CompanyInternal neuromodulation systems (implantable SCS, DBS, VNS),External neuromodulation systems and accessories,Radiofrequency and intraosseous nerve ablation for pain,
      ABBOTTUnited StatesPublic CompanyInternal neuromodulation – Spinal cord stimulation,Internal neuromodulation – Deep brain stimulation,Internal neuromodulation – Vagus nerve and other implants,
      LIVANOVA PLCUnited KingdomPublic CompanyInternal Vagus Nerve Stimulation for Epilepsy,Internal Vagus Nerve Stimulation for Depression,Other Neuromodulation (including aura6000 OSA development),
      NEVRO CORP.United StatesPrivate CompanyInternal SCS systems (Senza, Senza II, Senza Omnia, HFX iQ IPG),Surgical and percutaneous leads,Trial stimulators, remotes, and HFX App / digital,
      NEUROPACE, INC.United StatesPublic CompanyInternal neuromodulation – Deep brain–adjacent epilepsy (RNS neurostimulator + leads),Digital platforms and data services (nSight, patient data management, physician tablet ecosystem),Accessories and disposables (non-implantable components, remote monitors, ancillary hardware),
      BIOVENTUSUnited StatesPublic CompanyExternal / Peripheral Neuromodulation (Stimrouter, TalisMann, Exogen-related pain pathways),Surgical Ultrasonic Systems (neXus, BoneScalpel, SonaStar, SonicOne) in Neuro and Spine,Bone Graft Substitutes and Restorative Therapies in Neuro/Spine Settings,
      ELECTROCORE, INC.United StatesPublic CompanyExternal VNS – gammaCore (migraine, cluster, other headache),General wellness nVNS – Truvaga 350 and Truvaga Plus,Human performance and other non-invasive bioelectronic therapies (TAC-STIM, chronic pain, performance),
      HELIUS MEDICAL TECHNOLOGIES, INC.United StatesPublic CompanyExternal neuromodulation – PoNS for gait and balance deficits,Other neurological wellness and digital programs,Other digital asset / treasury-related activities,
      NEURONETICSUnited StatesPublic CompanyExternal neuromodulation – TMS for Depression (Clinics & Psychiatrist Offices),External neuromodulation – Hospital-based TMS Programs,Other neuromodulation applications (Ischemia, Epilepsy, Obesity; emerging geographies and pilots),
      NEUROSIGMA, INC.United StatesPrivate CompanyExternal Neuromodulation – Trigeminal Nerve Stimulation (eTNS/TNS) for ADHD,External Neuromodulation – TNS for Epilepsy and LGS (early commercialization),External Neuromodulation – TNS for Depression, PTSD, TBI,

      BIOGEN

      Biogen is a United States-based biotechnology company founded in 1978 with 7,500 employees. Operating as a public company, Biogen focuses on developing and commercializing therapies for neurological and neurodegenerative diseases.

      MEDTRONIC

      Medtronic is a multinational medical device company headquartered in Ireland, founded in 1949 with 95,000 employees. As a public company, Medtronic develops and manufactures a broad range of medical devices and therapies across multiple therapeutic areas.

      BOSTON SCIENTIFIC CORPORATION

      Boston Scientific Corporation is a United States-based medical device company founded in 1979 with 59,000 employees. The public company designs, manufactures, and markets medical devices used in interventional medical specialties.

      ABBOTT

      Abbott is a diversified healthcare company founded in the United States in 1888 with 115,000 employees. Operating as a public company, Abbott develops pharmaceuticals, medical devices, diagnostics, and nutritional products.

      LIVANOVA PLC

      LivaNova PLC is a United Kingdom-based medical device company founded in 2015 with 3,300 employees. The public company specializes in neuromodulation and cardiac surgery solutions.

      NEVRO CORP.

      Nevro Corp. is a United States-based medical device company founded in 2006 with 1,099 employees. Operating as a private company, Nevro develops neuromodulation therapies for chronic pain management.

      NEUROPACE, INC.

      NeuroPace, Inc. is a United States-based medical device company founded in 1997 with 220 employees. The public company develops and commercializes neurostimulation technology for neurological disorders.

      BIOVENTUS

      BioVentus is a United States-based medical device company founded in 2011 with 940 employees. Operating as a public company, BioVentus focuses on orthopedic and regenerative medicine solutions.

      ELECTROCORE, INC.

      ElectroCore, Inc. is a United States-based bioelectronic medicine company founded in 2005 with 83 employees. The public company develops non-invasive vagus nerve stimulation therapies for various conditions.

      HELIUS MEDICAL TECHNOLOGIES, INC.

      Helius Medical Technologies, Inc. is a United States-based medical device company with 21 employees. Operating as a public company, Helius develops neurorehabilitation technologies.

      NEURONETICS

      Neuronetics is a United States-based medical device company founded in 2001 with 658 employees. The public company develops and commercializes neuromodulation therapies for psychiatric and neurological conditions.

      NEUROSIGMA, INC.

      NeuroSigma, Inc. is a United States-based neurotechnology company founded in 2008 with 11 employees. Operating as a private company, NeuroSigma develops bioelectronic therapies for neurological disorders.

      Reasons to Buy this Report

      • Market Size & Revenue Projections : Access precise US market valuation ($2.9B in 2025) and detailed 5-year forecasts ($4.5B by 2030) to inform investment decisions, product launches, and market entry strategies with confidence.
      • Competitive Landscape Analysis : Understand market share distribution, key player strategies, and competitive positioning specific to the US market to identify partnership opportunities and differentiation strategies.
      • Reimbursement & Regulatory Insights : Gain detailed knowledge of US Medicare/Medicaid coverage policies, FDA approval pathways, and insurance reimbursement trends to optimize commercialization and market access strategies.
      • Segment & Application Breakdown : Identify high-growth therapeutic segments (pain management, movement disorders, epilepsy) and device types within the US market to prioritize R&D investments and commercial focus areas.
      • Strategic Growth Opportunities : Discover emerging trends, unmet clinical needs, and white-space opportunities in the US neuromodulation market to guide product innovation and market expansion initiatives.

      Frequently asked questions

      What is the current size of the US neuromodulation market?

      The US neuromodulation market is valued at $2,893.1 million in 2025 and is expected to reach $4,470.6 million by 2030.

      What is the projected growth rate for the US neuromodulation market?

      The US neuromodulation market is projected to grow at a compound annual growth rate (CAGR) of 9.1% from 2025 to 2030.

      What are the primary drivers of growth in the US neuromodulation market?

      Key drivers include rising prevalence of chronic pain and neurological disorders, an aging population, strong reimbursement policies, and FDA-accelerated regulatory pathways that enable rapid device innovation in the US.

      Which neuromodulation technologies are most prevalent in the US market?

      Spinal cord stimulation, deep brain stimulation, and peripheral nerve stimulation are the dominant technologies in the US neuromodulation market, driven by clinical efficacy and widespread healthcare provider adoption.

      How does the US neuromodulation market compare to global markets?

      The US neuromodulation market, growing at 9.1% CAGR, slightly outpaces the global market growth rate of 9.4%, reflecting the US market's maturity, innovation capacity, and robust healthcare infrastructure.

      RESEARCH METHODOLOGY

      The study involved key activities in estimating the current market size for the neuromodulation industry. Exhaustive secondary research was conducted to gather information on the neuromodulation sector. The next step was to validate these findings, assumptions, and estimates with industry experts across the value chain through primary research. Different methods, such as top-down and bottom-up approaches, were used to determine the total market size. Subsequently, market segmentation and data triangulation procedures were applied to estimate the market size of segments and subsegments within the neuromodulation market.

      The four steps involved in estimating the market size are:

      Secondary Research

      The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), , Global Burden of Disease Study, and Centers for Medicare and Medicaid Services (CMS) were referred to identify and collect information for the global neuromodulation market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and other key executives from various companies and organizations in the neuromodulation market. The primary sources from the demand side include biotechnology companies, CROs, pharmacies, medical device companies, and research academics and universities. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on important industry trends and key market dynamics.

      The following is a breakdown of the primary respondents:

      Neuromodulation Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      For the global market value, annual revenues were calculated based on revenue mapping of major product manufacturers and OEMs active in the worldwide neuromodulation market. All key service providers were identified at the global and/or country/regional level. Revenue mapping for the relevant business segments/sub-segments was performed for the major players. The global neuromodulation market was split into various segments and sub-segments based on:

      • List of major players operating in the products market at the regional and/or country level
      • Product mapping of neuromodulation providers at the regional and/or country level
      • Mapping of annual revenue generated by listed major players from neuromodulation (or the nearest reported business unit/product category)
      • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
      • Summation of the market value of all segments/subsegments to arrive at the global neuromodulation market

      The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

      The research methodology used to estimate the market size includes the following:

      Neuromodulation Market

      Data Triangulation

      After determining the overall market size using the process described above, the total market was divided into several segments. To finalize the market engineering process and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown methods were employed where applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Neuromodulation is a medical technology that modifies nerve activity by delivering targeted stimulation to specific areas of the body. It covers a broad range of therapies, from managing chronic pain—which is the most common use—to treating neurological and urological disorders, as well as movement disorders like Parkinson’s disease. By directly affecting neural pathways, neuromodulation can restore function, alleviate symptoms, and enhance quality of life, with ongoing innovations making it a rapidly growing field in modern medicine healthcare.

      Stakeholders

      • Neuromodulation and related device manufacturing companies
      • Equipment manufacturers
      • Suppliers and distributors of neuromodulation devices
      • Healthcare service providers
      • Teaching hospitals and academic medical centers (AMCs)
      • Health insurance players
      • Research and consulting firms
      • Medical research institutes
      • Healthcare institutions/providers (hospitals, medical groups, physicians’ practices, diagnostic centers, and outpatient clinics)
      • Venture capitalists
      • Community centers

      Report Objectives

      • To define, describe, segment, and forecast the global neuromodulation market by technology, stimulation type, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall neuromodulation market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

      Get the Full Neuromodulation Market Report

      Full forecast, segment splits, and company analysis for all Neuromodulation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status